·606·中华内科杂志2023年6月第62卷第6期Chin J1 ntern Med.June2023.Val.62.No.6·标准与讨论·脊柱关节炎靶向药物治疗专家共识国家皮肤与免疫疾病临床医学研究中心（北京协和医院）中国医师协会风湿免疫专科医师分会中国康复医学会风湿免疫专业委员会中国研究型医院学会风湿免疫专业委员会通信作者：曾小峰，中国医学科学院北京协和医学院北京协和医院风湿免疫科国家皮肤与免疫疾病临床医学研究中心疑难重症及罕见病国家重点实验室风湿免疫病学教育部重点实验室，北京l00730,Email:xiaofeng.zeng@cstar.ogcn【摘要】脊柱关节炎(S即A)是一组以中轴骨和/或外周关节受累为主的慢性炎症性疾病，临床表现异质性强，是一组致残性疾病，严重影响患者的生活和躯体功能。近年来，一些针对S印A发病中起关键作用的炎性细胞因子和细胞内通路的靶向治疗药物已逐渐成为其重要的治疗手段。但如何针对S即A患者的疾病特点，精准且规范地选择与使用靶向药物，在合理选择的同时兼顾其安全性，使更多S即A患者获益是临床亟待规范的问题。国家皮肤与免疫疾病临床医学研究中心（北京协和医院）联合中国医师协会风湿免疫专科医师分会、中国康复医学会风湿免疫专业委员会和中国研究型医院学会风湿免疫专业委员会，依据循证医学证据及共识制定的国际规范制定了本共识，旨在为临床医师安全有效地使用靶向药物提供指引，提高我国S即A的规范治疗水平。【关键词】脊柱关节炎；靶向药物；共识基金项目：中国医学科学院医学与健康科技创新工程项目(2021-2M-1-005)1915Consensus on targeted drug therapy for spondyloarthritisNational Clinical Research Center for Dermatologic and Immunologic Diseases(Peking Union MedicalCollege Hospital):Rheumatology and Immunology Physicians Committee,Chinese Medical DoctorsAssociation;Rheumatology and Immunology Professional Committee,Chinese Association ofRehabilitation Medicine;Chinese Research Hospital Association Rheumatology and ImmunologyProfessional CommitteeCorresponding author:Zeng Xiaofeng,Department of Rheumatology and Clinical Immunology,PekingUnion Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,National Clinical Research Center for Dermatologic and Immunologic Diseases,Ministry of Science&Technology,State Key Laboratory of Complex Severe and Rare Diseases,Key Laboratory ofRheumatology and Clinical Immunology,Ministry of Education,Beijing 100730,China,Email:xiaofeng.zeng@cstar.org.cnAbstract Spondyloarthritis (SpA)is a group of chronic inflammatory conditions thatpredominantly involve the spine and/or peripheral joints.The clinical manifestations of SpA arediverse and disabling,with SpA adversely affecting the quality of life of patients.Many newmedications that target cytokines or pathways specific for the pathogenesis of SpA have beendeveloped and these are becoming increasingly important in the treatment of SpA.However,establishing how to identify the target patient population and standardizing the usage of these drugsare critical issues in the clinical application of these "targeted therapies".Under the leadership ofD01:10.3760/cma.i.cnl12138-20221031-00806收稿日期2022-10-31本文编辑胡朝晖引用本文：国家皮肤与免疫疾病临床医学研究中心（北京协和医院），中国医师协会风湿免疫专科医师分会，中国康复医学会风湿免疫专业委员会，等.脊柱关节炎靶向药物治疗专家共识[.中华内科杂志，2023,62(6606-618.D01:10.3760/cmaj.cml12138-20221031-00806.
